ES2630002T5 - Fármaco anticanceroso que contiene alfa,alfa,alfa-trifluorotimidina e inhibidor de timidina fosforilasa - Google Patents

Fármaco anticanceroso que contiene alfa,alfa,alfa-trifluorotimidina e inhibidor de timidina fosforilasa Download PDF

Info

Publication number
ES2630002T5
ES2630002T5 ES06712292T ES06712292T ES2630002T5 ES 2630002 T5 ES2630002 T5 ES 2630002T5 ES 06712292 T ES06712292 T ES 06712292T ES 06712292 T ES06712292 T ES 06712292T ES 2630002 T5 ES2630002 T5 ES 2630002T5
Authority
ES
Spain
Prior art keywords
cancer
dose
ftd
therapeutic drug
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06712292T
Other languages
English (en)
Spanish (es)
Other versions
ES2630002T3 (es
Inventor
Tomohiro Emura
Akira Mita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36740357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2630002(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/042,059 external-priority patent/US7799783B2/en
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of ES2630002T3 publication Critical patent/ES2630002T3/es
Application granted granted Critical
Publication of ES2630002T5 publication Critical patent/ES2630002T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES06712292T 2005-01-26 2006-01-25 Fármaco anticanceroso que contiene alfa,alfa,alfa-trifluorotimidina e inhibidor de timidina fosforilasa Expired - Lifetime ES2630002T5 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11/042,059 US7799783B2 (en) 2005-01-26 2005-01-26 Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
US42059 2005-01-26
JP2005165156 2005-06-06
JP2005165156 2005-06-06
PCT/JP2006/301097 WO2006080327A1 (ja) 2005-01-26 2006-01-25 α，α，α－トリフルオロチミジンとチミジンホスホリラーゼ阻害剤とを配合した抗癌剤

Publications (2)

Publication Number Publication Date
ES2630002T3 ES2630002T3 (es) 2017-08-17
ES2630002T5 true ES2630002T5 (es) 2024-09-19

Family

ID=36740357

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06712292T Expired - Lifetime ES2630002T5 (es) 2005-01-26 2006-01-25 Fármaco anticanceroso que contiene alfa,alfa,alfa-trifluorotimidina e inhibidor de timidina fosforilasa

Country Status (21)

Country Link
EP (1) EP1849470B2 (Direct)
JP (1) JP5576591B2 (Direct)
KR (1) KR101468216B1 (Direct)
AU (1) AU2006209547C1 (Direct)
BE (1) BE2017C028I2 (Direct)
CA (1) CA2594713A1 (Direct)
CY (2) CY2017029I2 (Direct)
DK (1) DK1849470T4 (Direct)
ES (1) ES2630002T5 (Direct)
FI (1) FI1849470T4 (Direct)
FR (1) FR17C1028I2 (Direct)
HU (2) HUE033306T2 (Direct)
LT (2) LT1849470T (Direct)
LU (1) LUC00036I2 (Direct)
NL (1) NL300889I2 (Direct)
PL (1) PL1849470T5 (Direct)
PT (1) PT1849470T (Direct)
RU (1) RU2394581C2 (Direct)
SI (1) SI1849470T2 (Direct)
TW (1) TWI362265B (Direct)
WO (1) WO2006080327A1 (Direct)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
EP1849470B2 (en) 2005-01-26 2024-03-20 Taiho Pharmaceutical Co., Ltd. Anticancer drug containing alpha, alpha, alpha-trifluorothymidine and thymidine phosphorylase inhibitor
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
ES2587381T3 (es) * 2007-04-25 2016-10-24 Cyclacel Limited Uso de sapacitabina para tratar una enfermedad proliferativa
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
PT2273983T (pt) 2008-05-09 2016-10-28 Gruenenthal Gmbh Processo para a preparação de uma formulação em pó intermediária e uma forma de dosagem sólida final sob utilização de uma etapa de congelamento por atomização
EP2303283A2 (en) * 2008-05-15 2011-04-06 Katholieke Universiteit Leuven K.U. Leuven R&D Anti-cancer combination therapy
PE20120572A1 (es) 2009-07-22 2012-06-06 Gruenenthal Chemie Forma de dosificacion de oxidacion estabilizada resistente a la manipulacion
BR112012001547A2 (pt) 2009-07-22 2016-03-08 Gruenenthal Gmbh forma de dosagem farmacêutica extrusada por fusão a quente
MX2013002377A (es) 2010-09-02 2013-04-29 Gruenenthal Gmbh Forma de dosificacion resistente a manipulacion que comprende una sal inorganica.
AU2011297892B2 (en) 2010-09-02 2014-05-29 Grunenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
NO2736495T3 (Direct) 2011-07-29 2018-01-20
MX348054B (es) 2011-07-29 2017-05-25 Gruenenthal Gmbh Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco.
EP2746404B1 (en) 2011-08-16 2017-12-06 Taiho Pharmaceutical Co., Ltd. Antitumor agent and therapeutic effect prediction method for patients with kras-mutated colorectal cancer
TWI503122B (zh) 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
TWI526210B (zh) * 2012-02-15 2016-03-21 Taiho Pharmaceutical Co Ltd Oral pharmaceutical composition
CA2864949A1 (en) 2012-02-28 2013-09-06 Grunenthal Gmbh Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
TWI585206B (zh) 2012-03-14 2017-06-01 Nisshin Pharma Inc A method for producing a composition containing a sulfur-containing amino acid
PT2838512T (pt) 2012-04-18 2018-11-09 Gruenenthal Gmbh Forma farmacêutica resistente à adulteração e resistente à libertação inesperada de alta quantidade (dose-dumping)
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CN104349779A (zh) * 2012-05-16 2015-02-11 诺华股份有限公司 Pi-3激酶抑制剂的剂量方案
KR101847252B1 (ko) * 2013-03-27 2018-04-09 다이호야쿠힌고교 가부시키가이샤 이리노테칸염산염 수화물을 함유하는 항종양제
EP2979700B1 (en) * 2013-03-27 2018-09-26 Taiho Pharmaceutical Co., Ltd. Antitumor agent including low dose irinotecan hydrochloride hydrate
TWI595879B (zh) * 2013-05-17 2017-08-21 大鵬藥品工業股份有限公司 Prediction of therapeutic effect in patients with colorectal cancer with TK1 protein hyperactivity
WO2014191397A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
JP6466417B2 (ja) 2013-05-29 2019-02-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 二峰性放出プロファイルを有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形
BR112016000194A8 (pt) 2013-07-12 2019-12-31 Gruenenthal Gmbh forma de dosagem resistente à violação contendo o polímero de acetato de etileno-vinila
LT3042669T (lt) 2013-09-06 2023-06-26 Taiho Pharmaceutical Co., Ltd. Priešvėžinis agentas ir stipriklis su priešvėžiniu poveikiu
MX371372B (es) 2013-11-26 2020-01-28 Gruenenthal Gmbh Preparacion de una composicion farmaceutica en polvo por medio de criomolienda.
CN106572980A (zh) 2014-05-12 2017-04-19 格吕伦塔尔有限公司 包含他喷他多的防篡改即释胶囊制剂
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
AU2016251854A1 (en) 2015-04-24 2017-10-19 Grunenthal Gmbh Tamper-resistant dosage form with immediate release and resistance against solvent extraction
JP2018526414A (ja) 2015-09-10 2018-09-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 乱用抑止性の即放性製剤を用いた経口過剰摂取に対する保護
EP3693019A1 (en) * 2016-01-08 2020-08-12 Taiho Pharmaceutical Co., Ltd. Anti-tumor agent containing immunomodulator
NZ745113A (en) 2016-02-05 2021-12-24 Taiho Pharmaceutical Co Ltd Method for treating cancer patients with severe renal impairment
EP3730935A4 (en) 2017-12-22 2022-02-23 Taiho Pharmaceutical Co., Ltd. METHOD OF DETECTING ANALOGUES OF TRIFLURIDIN AND/OR TIPIRACIL
US10866219B2 (en) 2017-12-22 2020-12-15 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine- and/or tipiracil-related substance
US10816517B2 (en) 2018-01-05 2020-10-27 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine-related substance by high-performance liquid chromatography
WO2019135405A1 (ja) 2018-01-05 2019-07-11 大鵬薬品工業株式会社 トリフルリジン由来の類縁物質の検出方法
US20260021045A1 (en) * 2024-07-17 2026-01-22 Jnd Therapeutics, Inc. Methods and formulations for treatment of liver cancer using trifluridine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2191340C (en) * 1995-03-29 2001-04-17 Shingo Yano Uracil derivatives, and antitumor effect potentiator and antitumor agent containing the same
US6255314B1 (en) * 1996-09-24 2001-07-03 Taiho Charmaceutical Co., Ltd. Cancerous metastasis inhibitors containing uracil derivatives
EP1849470B2 (en) 2005-01-26 2024-03-20 Taiho Pharmaceutical Co., Ltd. Anticancer drug containing alpha, alpha, alpha-trifluorothymidine and thymidine phosphorylase inhibitor

Also Published As

Publication number Publication date
AU2006209547B2 (en) 2011-05-26
DK1849470T4 (en) 2024-04-02
NL300889I1 (nl) 2017-08-14
FI1849470T4 (fi) 2024-03-22
PT1849470T (pt) 2017-09-22
CY2017029I1 (el) 2018-02-14
PL1849470T5 (pl) 2024-06-10
AU2006209547A1 (en) 2006-08-03
LT1849470T (lt) 2017-07-25
LUC00036I1 (Direct) 2017-10-02
EP1849470B2 (en) 2024-03-20
RU2007132181A (ru) 2009-03-10
CA2594713A1 (en) 2006-08-03
CY1119393T1 (el) 2018-02-14
ES2630002T3 (es) 2017-08-17
EP1849470B1 (en) 2017-06-21
FR17C1028I1 (Direct) 2017-09-29
LUC00036I2 (Direct) 2017-12-01
PL1849470T3 (pl) 2017-11-30
FR17C1028I2 (fr) 2018-11-02
JPWO2006080327A1 (ja) 2008-06-19
HUE033306T2 (hu) 2017-11-28
WO2006080327A1 (ja) 2006-08-03
DK1849470T3 (en) 2017-08-14
AU2006209547C1 (en) 2022-04-07
SI1849470T2 (sl) 2024-05-31
EP1849470A1 (en) 2007-10-31
LTPA2017024I1 (lt) 2017-08-10
TW200637562A (en) 2006-11-01
BE2017C028I2 (Direct) 2025-09-10
KR101468216B1 (ko) 2014-12-03
CY2017029I2 (el) 2018-02-14
TWI362265B (en) 2012-04-21
SI1849470T1 (sl) 2017-10-30
HUS1700032I1 (hu) 2017-09-28
RU2394581C2 (ru) 2010-07-20
KR20070104559A (ko) 2007-10-26
EP1849470A4 (en) 2010-12-08
LTC1849470I2 (lt) 2019-10-25
JP5576591B2 (ja) 2014-08-20
NL300889I2 (nl) 2018-01-16

Similar Documents

Publication Publication Date Title
ES2630002T5 (es) Fármaco anticanceroso que contiene alfa,alfa,alfa-trifluorotimidina e inhibidor de timidina fosforilasa
USRE46284E1 (en) Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
KR20100091978A (ko) 시티딘 탈아미노효소 억제제로서 2'-플루오로-2'-데옥시테트라하이드로우리딘
ES2385850T3 (es) Potenciador de radioterapia
JP2025013684A (ja) 重度腎機能障害を有する癌患者に対する治療方法
CA2644297A1 (en) Prevention and treatment of cancer and other diseases
ES2644237T3 (es) Tratamiento de neurotoxicidad asociada a combinaciones de 5-FU o sus profármacos e inhibidores de DPD
EP2268287B1 (en) Dosage regimens of an antitumor agent comprising deoxycytidine derivative
CN105263499B (zh) 用于癌症治疗的ro5503781、卡培他滨和奥沙利铂的组合
JP5066737B2 (ja) シチジン誘導体を含有する持続静脈内投与用抗腫瘍剤
US20060258736A1 (en) Dosing regimen
RU2482855C2 (ru) Противоопухолевое средство, включающее производное цитидина и карбоплатин
HK1115306A (en) ANTICANCER DRUG CONTAINING α, α, α-TRIFLUOROTHYMIDINE AND THYMIDINE PHOSPHORYLASE INHIBITOR
HK1150151A (en) Anti-tumor agent comprising cytidine derivative and carboplatin